Rapid and sustained efficacy of golimumab in the treatment of multirefractory uveitis associated with Behçet’s disease

Claudia Fabiani; Jurgen Sota; Donato Rigante; Antonio Vitale; Giacomo Emmi; Lorenzo Vannozzi; Rossella Franceschini; Daniela Bacherini; Bruno Frediani; Mauro Galeazzi; Gian Marco Tosi; Luca Cantarini

doi:10.1080/09273948.2017.1351573

Rapid and sustained efficacy of golimumab in the treatment of multirefractory uveitis associated with Behçet’s disease

Claudia Fabiani
, Jurgen Sota
, Donato Rigante
, Antonio Vitale
, Giacomo Emmi
, Lorenzo Vannozzi
, Rossella Franceschini
, Daniela Bacherini
, Bruno Frediani
, Mauro Galeazzi
, Gian Marco Tosi
, Luca Cantarini

IRCCS Istituto Clinico Humanitas - Rozzano (Milano)
University of Siena
University of Florence
Università degli Studi di Siena, Facoltà di Medicina e Chirurgia

Research output: Contribution to journal › Article

12 Citations (Scopus)

Abstract

PURPOSE: To evaluate golimumab (GOL) efficacy in the management of Behçet's disease (BD)-related uveitis. METHODS: We retrospectively collected data from 5 patients (8 eyes) with at least two recent relapses of uveitis, treated with GOL at the standard dose of 50 mg every 4 weeks. RESULTS: A complete control of intraocular inflammation was observed in 7/8 eyes (87.5%) at 12-month follow-up. The number of relapses 12 months before and after GOL initiation was 11 and 1, respectively. At baseline, four eyes had active retinal vasculitis (RV). At 3-month follow-up evaluation RV resolved in all eyes. Mean Best Corrected Visual Acuity was 6.93 ± 4.34 at baseline and 7.32 ± 3.87 at 12-months follow-up. CONCLUSION: We confirm GOL efficacy in reducing intraocular inflammation in BD, both in term of reduction in the number of uveitis relapses and in achieving a prompt resolution of active RV.

Original language	English
Pages (from-to)	58-63
Number of pages	6
Journal	Ocular Immunology and Inflammation
Volume	27
DOIs	https://doi.org/10.1080/09273948.2017.1351573
Publication status	Published - 2019

Keywords

Behçet's disease

Access to Document

10.1080/09273948.2017.1351573

Cite this

Fabiani, C., Sota, J., Rigante, D., Vitale, A., Emmi, G., Vannozzi, L., Franceschini, R., Bacherini, D., Frediani, B., Galeazzi, M., Tosi, G. M., & Cantarini, L. (2019). Rapid and sustained efficacy of golimumab in the treatment of multirefractory uveitis associated with Behçet’s disease. Ocular Immunology and Inflammation, 27, 58-63. https://doi.org/10.1080/09273948.2017.1351573

@article{ac0f0d6b78f043b7ba86c400c50fd524,

title = "Rapid and sustained efficacy of golimumab in the treatment of multirefractory uveitis associated with Beh{\c c}et{\textquoteright}s disease",

abstract = "PURPOSE: To evaluate golimumab (GOL) efficacy in the management of Beh{\c c}et's disease (BD)-related uveitis. METHODS: We retrospectively collected data from 5 patients (8 eyes) with at least two recent relapses of uveitis, treated with GOL at the standard dose of 50 mg every 4 weeks. RESULTS: A complete control of intraocular inflammation was observed in 7/8 eyes (87.5\%) at 12-month follow-up. The number of relapses 12 months before and after GOL initiation was 11 and 1, respectively. At baseline, four eyes had active retinal vasculitis (RV). At 3-month follow-up evaluation RV resolved in all eyes. Mean Best Corrected Visual Acuity was 6.93 ± 4.34 at baseline and 7.32 ± 3.87 at 12-months follow-up. CONCLUSION: We confirm GOL efficacy in reducing intraocular inflammation in BD, both in term of reduction in the number of uveitis relapses and in achieving a prompt resolution of active RV.",

keywords = "Beh{\c c}et's disease, Beh{\c c}et's disease",

author = "Claudia Fabiani and Jurgen Sota and Donato Rigante and Antonio Vitale and Giacomo Emmi and Lorenzo Vannozzi and Rossella Franceschini and Daniela Bacherini and Bruno Frediani and Mauro Galeazzi and Tosi, \{Gian Marco\} and Luca Cantarini",

year = "2019",

doi = "10.1080/09273948.2017.1351573",

language = "English",

volume = "27",

pages = "58--63",

journal = "Ocular Immunology and Inflammation",

issn = "0927-3948",

publisher = "Taylor and Francis Ltd.",

}

Fabiani, C, Sota, J, Rigante, D, Vitale, A, Emmi, G, Vannozzi, L, Franceschini, R, Bacherini, D, Frediani, B, Galeazzi, M, Tosi, GM & Cantarini, L 2019, 'Rapid and sustained efficacy of golimumab in the treatment of multirefractory uveitis associated with Behçet’s disease', Ocular Immunology and Inflammation, vol. 27, pp. 58-63. https://doi.org/10.1080/09273948.2017.1351573

TY - JOUR

T1 - Rapid and sustained efficacy of golimumab in the treatment of multirefractory uveitis associated with Behçet’s disease

AU - Fabiani, Claudia

AU - Sota, Jurgen

AU - Rigante, Donato

AU - Vitale, Antonio

AU - Emmi, Giacomo

AU - Vannozzi, Lorenzo

AU - Franceschini, Rossella

AU - Bacherini, Daniela

AU - Frediani, Bruno

AU - Galeazzi, Mauro

AU - Tosi, Gian Marco

AU - Cantarini, Luca

PY - 2019

Y1 - 2019

N2 - PURPOSE: To evaluate golimumab (GOL) efficacy in the management of Behçet's disease (BD)-related uveitis. METHODS: We retrospectively collected data from 5 patients (8 eyes) with at least two recent relapses of uveitis, treated with GOL at the standard dose of 50 mg every 4 weeks. RESULTS: A complete control of intraocular inflammation was observed in 7/8 eyes (87.5%) at 12-month follow-up. The number of relapses 12 months before and after GOL initiation was 11 and 1, respectively. At baseline, four eyes had active retinal vasculitis (RV). At 3-month follow-up evaluation RV resolved in all eyes. Mean Best Corrected Visual Acuity was 6.93 ± 4.34 at baseline and 7.32 ± 3.87 at 12-months follow-up. CONCLUSION: We confirm GOL efficacy in reducing intraocular inflammation in BD, both in term of reduction in the number of uveitis relapses and in achieving a prompt resolution of active RV.

AB - PURPOSE: To evaluate golimumab (GOL) efficacy in the management of Behçet's disease (BD)-related uveitis. METHODS: We retrospectively collected data from 5 patients (8 eyes) with at least two recent relapses of uveitis, treated with GOL at the standard dose of 50 mg every 4 weeks. RESULTS: A complete control of intraocular inflammation was observed in 7/8 eyes (87.5%) at 12-month follow-up. The number of relapses 12 months before and after GOL initiation was 11 and 1, respectively. At baseline, four eyes had active retinal vasculitis (RV). At 3-month follow-up evaluation RV resolved in all eyes. Mean Best Corrected Visual Acuity was 6.93 ± 4.34 at baseline and 7.32 ± 3.87 at 12-months follow-up. CONCLUSION: We confirm GOL efficacy in reducing intraocular inflammation in BD, both in term of reduction in the number of uveitis relapses and in achieving a prompt resolution of active RV.

KW - Behçet's disease

UR - http://hdl.handle.net/10807/105659

U2 - 10.1080/09273948.2017.1351573

DO - 10.1080/09273948.2017.1351573

M3 - Article

SN - 0927-3948

VL - 27

SP - 58

EP - 63

JO - Ocular Immunology and Inflammation

JF - Ocular Immunology and Inflammation

ER -

Rapid and sustained efficacy of golimumab in the treatment of multirefractory uveitis associated with Behçet’s disease

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this